Latest news with #EuropeanSocietyforRadiotherapyandOncology
New Straits Times
15-05-2025
- Health
- New Straits Times
USM researcher earns recognition for tongue cancer treatment
GEORGE TOWN: A researcher from Universiti Sains Malaysia (USM) has earned recognition at the recent European Society for Radiotherapy and Oncology (ESTRO) 2025 meeting in Vienna. Associate Professor Dr Gokula Kumar Appalanaido was awarded the Top-Scoring Abstract Certificate for his paper on organ preservation and treatment for tongue cancer, which was presented at the conference. He and his team presented the pioneering abstract and proffered paper entitled, "Hybrid HDRIBT followed by IMRT (HyBIRT) technique for the definitive treatment of oral tongue SCC (OTSCC) – first in human prospective study", placing it among the top five per cent of submissions globally. A Top-Scoring Abstract Certificate is awarded to researchers whose abstract receives the highest score during the abstract review process, typically at a conference or symposium. USM, in a statement today, said that the accolade also positions the university as the rising leader in advanced cancer research and treatment, particularly in the field of brachytherapy. USM is also among a few institutions in the world that were given the prestigious 'Centre of Excellence' status for head and neck cancer brachytherapy by BrachyAcademy, a Netherlands-based scientific group. Other members in the pioneering team that developed the HyBIRT technique at USM Bertam Medical Centre (PPUSMB) include Associate Professor Dr. Yusri Musa, Dr Ahmad Fakrurrozi Mohamad, Dr Jasmin Jalil and Associate Professor Dr Mohd Zahri Abdul Aziz. The HyBIRT technique is a groundbreaking organ and function-preservation approach in the treatment of tongue cancer. It represents a significant clinical advancement in the application of brachytherapy and radiotherapy - developed, implemented, and now internationally recognised, right here in Malaysia, it said, adding that the recognition at ESTRO 2025 is a testament to the strength of Malaysian talents in the global medical arena.
Telegraph
03-05-2025
- Health
- Telegraph
Two weeks of prostate cancer radiotherapy still saves lives, study finds
For many patients, radiotherapy is a standard treatment option that offers outcomes comparable to surgery, particularly for localised disease but schedules typically span several weeks, which can be burdensome for patients and put pressure on healthcare systems. For the new trial, 1,200 men with localised cancer were given either a short course of seven sessions over two and a half weeks, or a standard course of 39 sessions over eight weeks. Results showed that 72 per cent of men having the shorter treatment did not see their cancer return and did not need more treatment within the next 10 years, compared to 65 per cent of men in the standard group. Overall survival for the two-week group was 81 per cent compared with 79 per cent for traditional treatment. For both groups four per cent of men died from their cancer in the 10-year follow up. The shorter treatment group needed a total radiation of 42.7 gy (the unit for absorbed dose) compared to 72 gy for the eight-week group. Side effects were similar in both groups and were mostly mild to moderate. 'These findings confirm that the shorter course does not increase long-term side effects and provides equally durable cancer control', added Dr Camilla Thellenberg-Karlsson, of Umeå University. 'A major win' for patients The findings were welcomed by charities. Simon Grieveson, assistant director of research at Prostate Cancer UK, said: 'We welcome these results. It's fantastic news for men that this has shown the long-term benefits of a shorter course of radiotherapy, meaning that they could still receive the best possible treatment with fewer visits to the hospital. 'We've previously seen similar results from the UK-based PACE B trial, which has shown that using stereotactic ablative body radiotherapy – a form of radiotherapy which delivers high doses of radiation directly to tumours, reducing exposure to healthy tissue around the cancer – can cut down the number of treatment sessions to just five over a two-week period. 'These studies show us that shorter courses of radiotherapy can be just as effective for men compared to the more extensive radiotherapy regimes more commonly used.' The research was presented at ESTRO 2025, the annual congress of the European Society for Radiotherapy and Oncology. Prof Matthias Guckenberger, president of ESTRO, added: 'Shorter treatment schedules mean patients can return to their normal lives more quickly. 'Reducing treatment time to just two and a half week is a major win for both patients and health systems.'
